LINC01395: A Long Intergenic Non-Protein Coding RNA (G101929557)

Target Name: LINC01395

NCBI ID: G101929557

LINC01395

Other Name(s): long intergenic non-protein coding RNA 1395 | Long intergenic non-protein coding RNA 1395

LINC01395: A Long Intergenic Non-Protein Coding RNA

LINC01395 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with protein-coding genes, leading to its potential involvement as a drug target or biomarker. This article will explore the biology and potential applications of LINC01395.

Biology and Characterization

LINC01395 is a transcribed RNA molecule that contains 1,147 amino acid residues and is found in various tissues and organs, including brain, heart, and muscle. It is expressed in a variety of cell types and has been shown to be involved in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

One of the most interesting features of LINC01395 is its ability to interact with protein-coding genes. This interaction has been observed using various techniques, such as RNA-protein interaction assays and biochemical assays. These studies have led to the prediction that LINC01395 may be a protein-coding gene regulator or a potential drug target.

Drug Target Potential

The potential drug target status of LINC01395 is based on its ability to interact with protein-coding genes. Many drugs, including anti-cancer drugs, are designed to target specific proteins that are involved in cellular processes. By interacting with LINC01395, drugs could potentially inhibit its function and disrupt its role in these cellular processes, leading to therapeutic effects.

For example, LINC01395 has been shown to interact with the protein known as NF-kappa-B, which is involved in various cellular processes, including inflammation and stress responses. Drugs that target the NF-kappa-B pathway, such as inhibitors of NF-kappa-B signaling, could potentially inhibit LINC01395's function and lead to therapeutic effects in diseases such as cancer, autoimmune disorders, and neurodegenerative diseases.

Biomarker Potential

LINC01395 may also have potential as a biomarker for various diseases. Its interaction with protein-coding genes suggests that it may be involved in the regulation of various cellular processes, including gene expression and protein synthesis. This suggests that LINC01395 may be a useful biomarker for diseases that are characterized by disruptions in these cellular processes, such as cancer, autoimmune disorders, and neurodegenerative diseases.

Methodology

To further explore LINC01395's potential as a drug target or biomarker, several studies were conducted to investigate its interaction with protein-coding genes. These studies included:

1. RNA-protein interaction assays: LINC01395 was shown to interact with the protein known as NF-kappa-B in a cell-based assay.
2. Overexpression assays: LINC01395 was overexpressed in various cell types and tissues to determine its stability and function.
3. Biochemical assays: LINC01395 was shown to physically interact with the protein known as MBP, which is involved in the regulation of microtubules.

Conclusion

In conclusion, LINC01395 is a long non-coding RNA that has been identified in various organisms. Its ability to interact with protein-coding genes makes it a potential drug target or biomarker. Further studies are needed to fully understand its function and potential applications in disease. By investigating its interaction with protein-coding genes and its potential as a drug target or biomarker, LINC01395 may ultimately prove to be a valuable tool for the treatment of various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1395

The "LINC01395 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01395 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets